Neffy® Epinephrine Nasal Spray: A Game-Changer for Allergy Sufferers Now Available Nationwide
Sep 23, 2024
For millions of Americans with severe allergies, the fear of experiencing a life-threatening allergic reaction, such as anaphylaxis, is a constant worry. Fortunately, ARS Pharmaceuticals, Inc. has introduced a groundbreaking solution with neffy®, the first and only needle-free epinephrine nasal spray, now available by prescription across the United States. Approved by the U.S. Food and Drug Administration (FDA) in August 2024, neffy offers an innovative alternative to traditional epinephrine auto-injectors, making it easier for patients to carry and use life-saving medication.
A Safer, Needle-Free Option for Anaphylaxis Treatment
Anaphylaxis is a rapid and severe allergic reaction that requires immediate treatment with epinephrine. Until now, epinephrine was primarily available through auto-injectors, which use needles. However, many patients hesitate to use these devices due to needle-related fears, leading to delays in treatment. Neffy® addresses this concern by delivering epinephrine intranasally, providing a simple and needle-free solution that is quick and easy to use.
According to ARS Pharmaceuticals, neffy is available for adults and children weighing 30 kg (66 lbs.) or more. Through the neffyConnect program and the partnership with BlinkRx, eligible commercially insured patients can obtain two single-use neffy devices for as low as $25, with a $199 cash price option for uninsured patients. For those who qualify, neffy is also available free of charge through the ARS Patient Assistance Program. Starting today, major pharmacies nationwide will stock neffy.
Easy Access and Financial Assistance
One of the key features of neffy is the ease of obtaining a prescription. Patients can visit their healthcare provider or utilize neffyConnect for a virtual consultation with a licensed physician. Once prescribed, patients can purchase neffy through retail pharmacies or online platforms like BlinkRx, ensuring widespread accessibility.
The neffyConnect service offers comprehensive financial assistance options, and eligible patients can download a $25 co-pay savings card directly from neffy.com. This service ensures that more patients can access the medication they need without facing significant financial barriers.
Impact on the Allergy Community
Dr. Carlos Camargo, Professor of Emergency Medicine at Massachusetts General Hospital and Harvard Medical School, notes that neffy represents a significant advancement for patients with severe allergic reactions. “With the introduction of neffy, we’re changing how we manage severe allergies. By eliminating the needle, we’re removing a major barrier to timely treatment, which can lead to better outcomes and fewer emergency room visits.”
Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharmaceuticals, also highlights the importance of this product: “The entire allergy community has worked for years to bring a needle-free epinephrine solution to market. With neffy, we are excited to see how this product improves the lives of up to 40 million Americans at risk of severe allergic reactions.”
Expanding Access Globally
In addition to its U.S. launch, ARS Pharmaceuticals plans to expand neffy® into European markets under the trade name EURneffy. The European Commission approved EURneffy in August 2024, and the company expects availability in certain EU Member States by the end of the year.
Furthermore, ARS Pharmaceuticals is working to expand neffy’s use in pediatric populations. A supplemental New Drug Application (sNDA) has been submitted to the FDA to approve neffy for children weighing between 15 and 30 kg (33-66 lbs.).
About Neffy® and Epinephrine
Epinephrine is the first line of defense for treating severe allergic reactions, including anaphylaxis. Traditional epinephrine auto-injectors, while effective, often present challenges such as needle fear, portability issues, and complexity. Neffy® simplifies treatment by offering a needle-free, portable option that can be easily administered through the nose.
Important Safety Information:
• Neffy should be administered in the nose only.
• Patients should carry two single-use neffy devices at all times.
• In case of inadequate response to the first dose, a second dose can be administered in the same nostril five minutes later.
• Neffy may cause side effects such as nasal discomfort, dizziness, or throat irritation. Patients with heart conditions or other underlying health issues should consult their doctor before use.
For more detailed safety information, please refer to the full prescribing information at neffy.com.
Wrapping up
Neffy® is a groundbreaking advancement in the treatment of severe allergies, offering a needle-free, user-friendly option that can be easily carried and administered in emergency situations. With its availability in pharmacies nationwide and affordable access through neffyConnect, patients at risk of anaphylaxis now have a life-saving alternative that is convenient and effective.
Visit neffy to learn more and explore available resources, including financial assistance programs.
For more information on allergy-safe snacks, check out our nut-free snack options to complement your allergy management plan.
A Safer, Needle-Free Option for Anaphylaxis Treatment
Anaphylaxis is a rapid and severe allergic reaction that requires immediate treatment with epinephrine. Until now, epinephrine was primarily available through auto-injectors, which use needles. However, many patients hesitate to use these devices due to needle-related fears, leading to delays in treatment. Neffy® addresses this concern by delivering epinephrine intranasally, providing a simple and needle-free solution that is quick and easy to use.
According to ARS Pharmaceuticals, neffy is available for adults and children weighing 30 kg (66 lbs.) or more. Through the neffyConnect program and the partnership with BlinkRx, eligible commercially insured patients can obtain two single-use neffy devices for as low as $25, with a $199 cash price option for uninsured patients. For those who qualify, neffy is also available free of charge through the ARS Patient Assistance Program. Starting today, major pharmacies nationwide will stock neffy.
Easy Access and Financial Assistance
One of the key features of neffy is the ease of obtaining a prescription. Patients can visit their healthcare provider or utilize neffyConnect for a virtual consultation with a licensed physician. Once prescribed, patients can purchase neffy through retail pharmacies or online platforms like BlinkRx, ensuring widespread accessibility.
The neffyConnect service offers comprehensive financial assistance options, and eligible patients can download a $25 co-pay savings card directly from neffy.com. This service ensures that more patients can access the medication they need without facing significant financial barriers.
Impact on the Allergy Community
Dr. Carlos Camargo, Professor of Emergency Medicine at Massachusetts General Hospital and Harvard Medical School, notes that neffy represents a significant advancement for patients with severe allergic reactions. “With the introduction of neffy, we’re changing how we manage severe allergies. By eliminating the needle, we’re removing a major barrier to timely treatment, which can lead to better outcomes and fewer emergency room visits.”
Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharmaceuticals, also highlights the importance of this product: “The entire allergy community has worked for years to bring a needle-free epinephrine solution to market. With neffy, we are excited to see how this product improves the lives of up to 40 million Americans at risk of severe allergic reactions.”
Expanding Access Globally
In addition to its U.S. launch, ARS Pharmaceuticals plans to expand neffy® into European markets under the trade name EURneffy. The European Commission approved EURneffy in August 2024, and the company expects availability in certain EU Member States by the end of the year.
Furthermore, ARS Pharmaceuticals is working to expand neffy’s use in pediatric populations. A supplemental New Drug Application (sNDA) has been submitted to the FDA to approve neffy for children weighing between 15 and 30 kg (33-66 lbs.).
About Neffy® and Epinephrine
Epinephrine is the first line of defense for treating severe allergic reactions, including anaphylaxis. Traditional epinephrine auto-injectors, while effective, often present challenges such as needle fear, portability issues, and complexity. Neffy® simplifies treatment by offering a needle-free, portable option that can be easily administered through the nose.
Important Safety Information:
• Neffy should be administered in the nose only.
• Patients should carry two single-use neffy devices at all times.
• In case of inadequate response to the first dose, a second dose can be administered in the same nostril five minutes later.
• Neffy may cause side effects such as nasal discomfort, dizziness, or throat irritation. Patients with heart conditions or other underlying health issues should consult their doctor before use.
For more detailed safety information, please refer to the full prescribing information at neffy.com.
Wrapping up
Neffy® is a groundbreaking advancement in the treatment of severe allergies, offering a needle-free, user-friendly option that can be easily carried and administered in emergency situations. With its availability in pharmacies nationwide and affordable access through neffyConnect, patients at risk of anaphylaxis now have a life-saving alternative that is convenient and effective.
Visit neffy to learn more and explore available resources, including financial assistance programs.
For more information on allergy-safe snacks, check out our nut-free snack options to complement your allergy management plan.
